MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Abbott Laboratories Operating Income 2011-2026 | ABT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Abbott Laboratories
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.05 B | 6.82 B | 6.48 B | 8.36 B | 8.42 B | 5.36 B | 4.53 B | 3.65 B | 1.56 B | 3.03 B | 2.87 B | 2.6 B | 2.13 B | 1.36 B | 1.63 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.42 B | 1.36 B | 4.46 B |
Quarterly Operating Income Abbott Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.05 B | 1.69 B | 1.86 B | 1.67 B | 1.39 B | 1.65 B | 1.54 B | 1.51 B | - | 1.77 B | 2.38 B | 2.91 B | - | 2.55 B | 1.39 B | 2.11 B | - | 1.5 B | 672 M | 758 M | - | 1.2 B | 1.21 B | 739 M | - | 995 M | 882 M | 608 M | - | 769 M | 386 M | -242 M | - | 897 M | 816 M | 524 M | - | 713 M | 729 M | 610 M | - | 728 M | 677 M | 365 M | - | 473 M | 627 M | 615 M | - | 310 M | 564 M | 509 M | - | 595 M | 1.77 B | 1.3 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.91 B | -242 M | 1.11 B |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B |  USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.35 | - | $ 21.8 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
LENSAR
LNSR
|
-10.7 M | $ 5.56 | -8.4 % | $ 64 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Penumbra
PEN
|
189 M | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Insulet Corporation
PODD
|
474 M | $ 225.5 | -0.7 % | $ 15.9 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.15 | -4.63 % | $ 180 M | Canada |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Quanterix Corporation
QTRX
|
-126 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-56.7 M | $ 2.4 | -1.64 % | $ 141 M |  Israel |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
-66.7 M | $ 3.53 | -2.35 % | $ 53.7 K | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 52.07 | -0.17 % | $ 1.53 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.57 | 0.78 % | $ 7.13 M | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.31 | -5.76 % | $ 53.3 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Sensus Healthcare
SRTS
|
-10.3 M | $ 3.96 | -3.65 % | $ 64.7 M | USA |
 |
InspireMD
NSPR
|
-49.6 M | $ 1.79 | 3.47 % | $ 115 M | Israel |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |